Dataset from A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00008400
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the
safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel
and carboplatin, and gemcitabine in participants with solid tumors.
创建时间：
2025-10-01
